CRISPR Therapeutics Stock Forecast, Price & News

CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than CRISPR Therapeutics?

Wall Street analysts have given CRISPR Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CRISPR Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for CRISPR Therapeutics.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) announced its quarterly earnings results on Thursday, July, 29th. The company reported $9.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.52 by $5.92. The business earned $900.70 million during the quarter, compared to analysts' expectations of $678.05 million. CRISPR Therapeutics had a trailing twelve-month return on equity of 24.08% and a net margin of 49.52%.
View CRISPR Therapeutics' earnings history.

How has CRISPR Therapeutics' stock been impacted by Coronavirus?

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRSP shares have increased by 124.1% and is now trading at $97.00.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CRSP?

17 equities research analysts have issued 1 year price targets for CRISPR Therapeutics' shares. Their forecasts range from $101.00 to $210.00. On average, they anticipate CRISPR Therapeutics' stock price to reach $161.13 in the next year. This suggests a possible upside of 66.1% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics or view top-rated stocks among Wall Street analysts.

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:

• Rodger Novak, Chairman & President
• Samarth Kulkarni, Chief Executive Officer & Director (LinkedIn Profile)
• Lawrence O. Klein, Chief Operating & Business Officer
• Michael John Tomsicek, Chief Financial & Accounting Officer (LinkedIn Profile)
• Tony W. Ho, Executive VP, Head-Research & Development

Who are some of CRISPR Therapeutics' key competitors?

Some companies that are related to CRISPR Therapeutics include Bio-Techne (TECH), Novozymes A/S (NVZMY), argenx (ARGX), Repligen (RGEN), Novavax (NVAX), QIAGEN (QGEN), Acceleron Pharma (XLRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Beam Therapeutics (BEAM), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Twist Bioscience (TWST), Denali Therapeutics (DNLI) and Halozyme Therapeutics (HALO).
View all of CRSP's competitors.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering (IPO) on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Carnegie Capital Asset Management LLC (0.16%), Ipswich Investment Management Co. Inc. (0.04%), Bouvel Investment Partners LLC (0.02%), Harbor Investment Advisory LLC (0.02%), Green Alpha Advisors LLC (0.02%) and Private Advisor Group LLC (0.02%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics.

Which major investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Winfield Associates Inc., Bouvel Investment Partners LLC, Harbor Investment Advisory LLC, and Wedbush Securities Inc.. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for CRISPR Therapeutics or view top insider-selling stocks.

Which major investors are buying CRISPR Therapeutics stock?

CRSP stock was acquired by a variety of institutional investors in the last quarter, including Northstar Advisory Group LLC, Private Advisor Group LLC, City Holding Co., Green Alpha Advisors LLC, Foundations Investment Advisors LLC, Carnegie Capital Asset Management LLC, Fifth Third Bancorp, and Ipswich Investment Management Co. Inc..
View insider buying and selling activity for CRISPR Therapeutics or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $97.00.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $7.39 billion and generates $720,000.00 in revenue each year. The company earns $-348.86 million in net income (profit) each year or ($5.29) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 410 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

Where are CRISPR Therapeutics' headquarters?

CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].